EA201500182A1 - 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ - Google Patents

4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ

Info

Publication number
EA201500182A1
EA201500182A1 EA201500182A EA201500182A EA201500182A1 EA 201500182 A1 EA201500182 A1 EA 201500182A1 EA 201500182 A EA201500182 A EA 201500182A EA 201500182 A EA201500182 A EA 201500182A EA 201500182 A1 EA201500182 A1 EA 201500182A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
pentaasacyclopent
naftail
application describes
methods
Prior art date
Application number
EA201500182A
Other languages
English (en)
Other versions
EA028958B1 (ru
Inventor
Риккардо Джованни
Барбара Бертани
Сэра Фраттини
Джустино Ди Антонио
Ханс-Йоахим Ланкау
Ханс Штанге
Кристиан Грунвальд
Норберт Хёфген
Барбара Ланген
Уте Эгерланд
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906250&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201500182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201500182A1 publication Critical patent/EA201500182A1/ru
Publication of EA028958B1 publication Critical patent/EA028958B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

В заявке описаны производные 4-метил-2,3,5,9,9b-пентаазациклопента[а]нафталина общей формулы (I), которые являются ингибиторами фосфодиэстеразы 2 и/или 10, применимыми для лечения заболеваний центральной нервной системы и других заболеваний. Кроме того, в заявке описаны способы приготовления фармацевтических композиций, а также способы получения соединений, предлагаемых в настоящем изобретении.
EA201500182A 2012-07-31 2013-07-29 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ EA028958B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12178713 2012-07-31
PCT/EP2013/065894 WO2014019979A1 (en) 2012-07-31 2013-07-29 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

Publications (2)

Publication Number Publication Date
EA201500182A1 true EA201500182A1 (ru) 2015-07-30
EA028958B1 EA028958B1 (ru) 2018-01-31

Family

ID=48906250

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500182A EA028958B1 (ru) 2012-07-31 2013-07-29 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ

Country Status (28)

Country Link
US (2) US20140045856A1 (ru)
EP (1) EP2882749B1 (ru)
JP (1) JP6356671B2 (ru)
KR (1) KR20150037950A (ru)
CN (1) CN104428302B (ru)
AP (1) AP2015008202A0 (ru)
AR (1) AR091939A1 (ru)
AU (1) AU2013298621B2 (ru)
BR (1) BR112015002118A2 (ru)
CA (1) CA2880447A1 (ru)
CL (1) CL2015000096A1 (ru)
CO (1) CO7310531A2 (ru)
EA (1) EA028958B1 (ru)
EC (1) ECSP15006871A (ru)
GE (1) GEP201706707B (ru)
HK (1) HK1208440A1 (ru)
IL (1) IL236494A0 (ru)
MA (1) MA37798B1 (ru)
MX (1) MX2015000965A (ru)
NZ (1) NZ703797A (ru)
PE (1) PE20150706A1 (ru)
PH (1) PH12015500211B1 (ru)
SG (1) SG11201500772VA (ru)
TN (1) TN2015000022A1 (ru)
TW (1) TW201418255A (ru)
UA (1) UA115561C2 (ru)
UY (1) UY34955A (ru)
WO (1) WO2014019979A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US9056863B2 (en) * 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016184313A1 (zh) * 2015-05-20 2016-11-24 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
CA3054674A1 (en) * 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
AR112457A1 (es) * 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
JP2021504466A (ja) 2017-11-23 2021-02-15 オスロ ウニヴェルシティ ホスピタル ホーエフ 頻脈の治療

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000319278A (ja) * 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP2000319277A (ja) * 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
EP1613629A1 (en) 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
EP1697356B1 (en) 2003-12-16 2008-02-27 Pfizer Products Incorporated Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
FR2865331A1 (fr) 2004-01-21 2005-07-22 France Telecom Procede de connexion d'un reseau domestique a un serveur cops distant et dispositif associe
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
EA014324B1 (ru) 2004-09-02 2010-10-29 Никомед Гмбх Триазолофталазины
CN101103033B (zh) 2005-01-05 2010-08-04 尼科梅德有限责任公司 作为pde2抑制剂的***并酞嗪
US7671050B2 (en) 2005-01-05 2010-03-02 Nycomed Gmbh Triazolophthalazines
BRPI0502411A (pt) 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
JP2009523820A (ja) 2006-01-23 2009-06-25 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼの三環系抑制剤
WO2007121319A2 (en) 2006-04-14 2007-10-25 University Of California Compostions and methods for determining and predicting treatment responses for depression and anxiety
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
CA2735369A1 (en) 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP2012505231A (ja) 2008-10-08 2012-03-01 ブリストル−マイヤーズ スクイブ カンパニー アゾロピロロンメラニン凝集ホルモン受容体−１アンタゴニスト
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
EP2406250B1 (en) * 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
CN103619841B (zh) * 2011-01-11 2017-03-29 桑诺维恩药品公司 杂芳基化合物及其使用方法
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

Also Published As

Publication number Publication date
WO2014019979A1 (en) 2014-02-06
JP6356671B2 (ja) 2018-07-11
PH12015500211A1 (en) 2015-03-16
US20140045857A1 (en) 2014-02-13
SG11201500772VA (en) 2015-02-27
MX2015000965A (es) 2015-04-10
TW201418255A (zh) 2014-05-16
ECSP15006871A (es) 2015-12-31
TN2015000022A1 (en) 2016-06-29
UY34955A (es) 2014-01-31
AR091939A1 (es) 2015-03-11
CN104428302A (zh) 2015-03-18
US20140045856A1 (en) 2014-02-13
CO7310531A2 (es) 2015-06-30
BR112015002118A2 (pt) 2017-07-04
AP2015008202A0 (en) 2015-01-31
MA37798B1 (fr) 2018-11-30
PE20150706A1 (es) 2015-06-03
EP2882749A1 (en) 2015-06-17
EP2882749B1 (en) 2018-04-04
CN104428302B (zh) 2017-03-22
AU2013298621B2 (en) 2017-12-21
CL2015000096A1 (es) 2015-06-19
JP2015523406A (ja) 2015-08-13
EA028958B1 (ru) 2018-01-31
AU2013298621A1 (en) 2015-02-05
PH12015500211B1 (en) 2015-03-16
HK1208440A1 (en) 2016-03-04
KR20150037950A (ko) 2015-04-08
IL236494A0 (en) 2015-02-26
UA115561C2 (uk) 2017-11-27
CA2880447A1 (en) 2014-02-06
US9085584B2 (en) 2015-07-21
NZ703797A (en) 2017-09-29
GEP201706707B (en) 2017-07-25

Similar Documents

Publication Publication Date Title
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
IN2014KN00929A (ru)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201690752A1 (ru) Ингибиторы g12c kras
SA515360007B1 (ar) مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk)
MX368042B (es) COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR).
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
IN2014KN02410A (ru)
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201270339A1 (ru) Замещенные производные ксантина
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU